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Background and aims: 
Seronegative villous atrophy (SNVA), raised intraepithelial lymphocytes (IELs) and crypt 
hyperplasia on duodenal histology can be secondary to celiac disease (CD) or other causes 
such as medications or infections.  Our aims were to assess the role of small-bowel capsule 
endoscopy (SBCE) in these patients and to ascertain whether findings on SBCE at diagnosis 
can predict disease outcome.   
 
Methods: 
Patients (177) with SNVA, IELs +/-crypt hyperplasia on duodenal histology were studied.  
These patients all had an equivocal diagnosis of CD.  
 
Results: 
Overall, 56 (31.6%) patients had a positive SBCE. Most patients had disease affecting the 
proximal third of the small bowel (SB) (33, 58.9%). The diagnostic yield of SBCE was 
40.0% (22 patients), 51.4% (18 patients), 27.0% (10 patients), and 14.0% (7 patients) in 
patients with an unknown cause for SNVA (SNVA-UO), patients with SNVA who responded 
to a gluten-free diet (SNVA-CD), SNVA-KNOWN CAUSE, patients with railed 
intraepithelial lymphocytes +/- crypt hyperplasia respectively. In SNVA-UO, SBCE at 
diagnosis was more likely to be positive in patients with persistent SNVA (10, 90.9%) and 
persistent SNVA with lymphoproliferative features (4, 80.4%) than patients with spontaneous 
resolution of SNVA (8, 20.5%) (p=0.0001). All patients in the SNVA-CD group who 
eventually developed adverse events had a positive SBCE (p=0.022). They also had more 
extensive SB disease than those without adverse events (50% vs 1% p=0.002). More-
extensive SB disease on SBCE correlated with a higher SNVA-related mortality in patients 




A positive SBCE at diagnosis predicts a worse outcome. More importantly, more extensive 
disease in these patients is associated with poor survival. Targeting patients with extensive 
disease at diagnosis with more aggressive therapy can help to improve prognosis. 
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Although the criterion standard for the diagnosis of celiac disease (CD) is duodenal 
histology, celiac serology and genetic studies can be negative in the presence of villous 
atrophy (VA) (1, 2).  This has led to the introduction of another term: seronegative villous 
atrophy (SNVA).   
 
In patients with suspected CD, SNVA on duodenal histology can be secondary to IgA 
deficiency or a low gluten intake at the time of diagnosis (3, 4).  SNVA can also be 
secondary to drugs, infections and immune-mediated conditions (5).  In some patients, the 
cause remains unknown (6).  The most common causes for SNVA are as follows: CD 
(SNVA-CD) (28%-31%), medication-related (6%-26%), infective (7%-27%), and idiopathic 
(14%-18%) (5, 7).  Despite undergoing extensive investigations, determining the etiology of 
disease in most of these patients is challenging and requires further secondary investigations.  
The introduction of small-bowel capsule endoscopy (SBCE) has enabled us to study this 
condition further.  
 
Similar to SNVA, milder changes on duodenal histology of raised intraepithelial lymphocytes 
(IELs) and/or crypt hyperplasia can occur secondary to immune-mediated conditions, 
medications, and infections (8, 9).  These patients do not have enough changes on duodenal 
histology to support a diagnosis of CD as VA and positive CD serology are required features 
(10).  Some of these patients will eventually have a confirmative diagnosis of CD (11).  One 
explanation is that CD can affect the small bowel (SB) with varying degrees of severity (12).  
Some patients might be following a low-gluten-containing diet, and changes will only 
become evident after a gluten challenge. 
 
As recommended by the European guidelines, SBCE is indicated in patients with equivocal 
CD (13).  Up to 30% of patients with CD present with persisting signs and symptoms, which 
necessitates further investigations, including repeat duodenal histology and SBCE (14).  
SBCE can play a major role in patients with refractory celiac disease (RCD) in assessing 
disease extent and ruling out adverse events at diagnosis (15) and at follow-up (16).    
 
Our aim was to assess the role of SBCE in patients with distinct causes for SNVA and Marsh 
1 and 2 histology. Firstly, we determined whether SBCE can play a role at diagnosis in 
addition to conventional investigations. Secondly, we examined findings on SBCE to assess 
whether they can help predict outcomes.   
 
Methodology:  
Study design and participants: 
One hundred seventy-seven patients with SNVA or raised intraepithelial lymphocytes (IELs) 
+/- crypt hyperplasia  on duodenal histology were prospectively recruited over a 19-year 
period (2000 – 2019).  They all had a SBCE after a histological diagnosis, total 
immunoglobulin A levels (IgA) and contemporary CD serology (IgA endomysial antibodies, 
EMA and IgA tissue transglutaminase antibodies anti-TTG). All patients had negative EMA 
and anti-TTG levels.   
 
Patients with SNVA or raised IELs +/- crypt hyperplasia on duodenal histology referred to 
the SB unit for SBCE by their respective caring physician within the study period were 
included in this study.  The caring physician, then determined the type of follow up (repeat 
duodenal histology and SBCE) these patients received.  
 
A separate group of patients with Marsh 1 and 2 histology was included in this study as these 
patients form part of the group of patients with an equivocal diagnosis of CD (17).  Absence 
of VA and negative CD serology in these patients can be explained by the patchy nature of 
CD in the SB, low gluten intake in the diet and incorrect orientation of the duodenal 
specimens (12, 18-20). They do not have enough histological changes (VA) to fulfill a 
diagnosis of CD and their CD serology is negative.  However, they have changes (raised IELs 
or / and crypt hyperplasia) that could be found in patients with CD or in those who will 
eventually develop CD as shown in previous studies (21, 22).   Our study provides a broader 
overview of patients with equivocal changes on histology that could potentially be related to 
CD by including patients with Marsh 1 and 2 histology. 
 
Duodenal histology: 
At least 2 biopsy specimens from the duodenal bulb (D1) and 4 specimens from the second 
part of the duodenum (D2) were taken. All duodenal biopsy specimens were fixed in buffered 
formalin and embedded in paraffin wax. Standard 3-m-thick sections at 3 levels were 
stained with hematoxylin and eosin. All histological samples were reviewed by 2 expert 
histopathologists. In the case of discrepancy, a third histopathologist was involved in the 
adjudication process.  IELs was defined as >25 per 100 enterocytes (23). VA was identified 
according to the Marsh-Oberhuber criteria, using the most-severe lesion present: Marsh 1 
(raised IELs), Marsh 2 (crypt hyperplasia), Marsh 3a (partial villous atrophy, PVA), Marsh 
3b (subtotal villous atrophy, SVA), or Marsh 3c (total villous atrophy, TVA) (24). 
 
Histological samples were also assessed for differences in immunohistochemistry based on 




CD serology testing was IgA based.  EMA were detected on immunofluoresence on primate 
oesophagus sections from The Binding Site (Birmingham, UK). Anti-TTG levels were 
assayed using ELISA kits (Aesku Diagnostics, Wendelsheim, Germany).  Titres less than or 
equal to 15U/mL were considered normal.  
 
Criteria for diagnosis of SNVA and categories of patients: 
Criteria for the diagnosis of SNVA were similar to those used by previous researchers (5, 7) 
including: 
 
1. Review of medical and surgical history and medication use. 
2. Patients underwent the following investigations, including HLA-DDQ2 and DQ8 
genetic studies, HIV serology, Tuberculosis quantiferon, antienterocyte and antigoblet 
cell antibodies, stools for giardia antigen and other bacteria.   
3. The biopsy specimens were reviewed by expert gastrointestinal histopathologists to 
confirm the diagnosis. 
4. If patients were on a gluten-free diet (GFD) at the time of presentation, they were 
asked to undergo a gastroduodenoscopy after a gluten-challenge of 10g/day for 6 
weeks.   
5. Further biopsy specimens were obtained to rule out Helicobacter pylori, Whipple’s 
PCR, and SB aspirate to rule out infection.   
6. In case of persistent symptoms or where the suspicion of Crohn’s disease / 
microscopic colitis was high, an ileocolonoscopy was carried out.   
7. SBCE at the time of diagnosis was carried out at the discretion of the physician but 
based on clinical need.   
 
For the purpose of this paper, a histological response (as opposed to a clinical response) to a 
GFD was considered to be diagnostic of SNVA-CD (group 2).  This is a stricter criteria than 
a clinical response to a GFD and eliminates the risk of diagnosing patients incorrectly as we 
know that in some patients, a clinical response to a GFD does not mirror a histological 
response (6).   
 
Patients with no identifiable cause for SNVA (SNVA-UO) all had alternative causes for 
SNVA excluded.  They were further subclassified into patients with (1) resolving /transient 
SNVA, (2) persistent histological changes and no response to a GFD, or (3) persistent 
histology despite a trial of GFD and with lymphoproliferative disorders before or after the 
diagnosis of SNVA (figure 1). 
 
Patients with SNVA-CD (group 2) had a histological response to a GFD.  Other supporting 
features included raised IgG celiac serology, features such as dermatitis herpetiformis, a 
positive first-degree family history of CD and HLA genotype supportive of a diagnosis of 
SNVA-CD.  
  
Patients in group 3 had a cause for VA in their medical history or by testing for infective and 
inflammatory conditions. Patients in group 4 had a diagnosis of Marsh grade 1 or 2 but no 
evidence of VA.   
 
All of these patients underwent extensive investigations as outlined in the criteria above and 
in Figure 1.   
 
Small-bowel capsule endoscopy: 
Each patient was asked to stay on clear fluids for 24 hours before the SBCE and to drink 2 
liters of Klean-Prep the day before the SBCE. All patients underwent SBCE using Pillcam 
SB 2 or 3 (Medtronic, Minneapolis, Minn, USA) (25, 26). SBCEs were reviewed by expert 
SBCE reviewers (>300 capsules each/ year). The expert reviewers of the capsule endoscopies 
were aware of the clinical picture including symptoms at presentation, findings on duodenal 
histology, serological results and findings on previous SBCEs. Findings such as fissuring of 
mucosa, scalloping of folds, mosaic pattern, nodularity, VA, and ulcers were recorded. 
Currently there is no validating scoring system for the diagnosis of CD on SBCE. Features 
associated with CD have been studied before.  These include fissuring of mucosa, scalloping 
of folds, mosaic pattern, nodularity, VA and ulcers (27-29). Hence, we used similar 
assessment for our patients in this study at the time of reporting.  A SBCE was considered to 
be positive (positive diagnostic yield, DY) if 3 or more features of CD mentioned above were 
present.   
The distribution (proximal, mid, distal, diffuse SB) and extent of affected SB mucosa was 
also recorded.  
 
In this study, extent of abnormal SB mucosa refers to SB mucosa with macroscopic features 
of CD.  
 
Statistical analysis: 
Statistical analysis was carried out using SPSS version 23 (IBM Corp. Released 2015. IBM 
SPSS Statistics for Mac, Version 23.0. Armonk, NY, USA: IBM Corp.). Frequencies and 
means were calculated to characterize each group. Nonparametric statistical tests were used 
namely, the Fishers exact test, and Kruskal–Wallis test Results were considered to be 
statistically significant if the p value was less than 0.05. 
 
Ethical considerations: 
The study protocol was approved by the Yorkshire and the Humber Research Ethics 
committee (IRAS 232382) and registered with the local research and development 
department of Sheffield Teaching Hospital NHS Foundation Trust under the registration 
number STH 19998. All images used in this study were deidentified. No additional consent 
was required for the study with the use of deidentified videos as assessed and approved 
formally by the Research Ethics Committee. 
 
Results: 
A total of 177 patients (107 females, 60.5%; mean age of 49.7+/-16.9 years) were included in 
this study.  A total of 177 patients (107 females, 60.5%; mean age of 49.7+/-16.9 years) were 
included in this study.  They underwent a SBCE within a median of 93 days from histological 
diagnosis.  The median time between index SBCE and repeat histology was 125 days.  Most 
patients only had proximal SB disease (33, 58.9%) (table 1) 
 
Only 5 patients (2.8%) had incomplete visualisation of the SB on SBCE.  One patient with 
diffuse features of SNVA on SBCE had a repeat complete SBCE that showed duodenitis 
only.  This patient had SNVA-UO.  Repeat duodenal histology showed persistent TVA.  Two 
patients (1 had raised IELs on histology, another patient had SNVA-UO) did not have any 
features of SNVA on SBCE and they did not undergo a repeat SBCE.  The patient with 
SNVA-UO and a normal SBCE had spontaneous resolution of SNVA confirmed on repeat 
duodenal histology.  Two patients with incomplete SBCE had proximal SB ulcers. One 
patient was treated for H pylori.  Another patient with a history of nonsteroidal anti-
inflammatory drug (NSAID) use underwent repeat duodenal histology that was normal after 
stopping NSAIDs for 6 months.     
 
There was no statistical difference in DY according to age at diagnosis (median age SBCE 
positive: 51 years, SBCE negative: 50 years; p=0.804), HLA status (p=0.608), ethnicity 
(p=0.531) and gender (p=0.188). 
 
Group 1 (SNVA-UO): 
Fifty-five (31.1%) had no identifiable cause for SNVA.  The DY of SBCE was 40% (22) in 
this group of patients.   
 
Thirty-nine patients (70.9%) had spontaneous resolution of SNVA on histology.  Eleven 
(20.0%) patients had persistent SNVA. Five (9.1%) patients had persistent SNVA and 
developed lymphoproliferative features.  SBCE was positive in 8 (20.5%) of those with 
spontaneous resolution of SNVA, 10 (90.9%) of patients with persistent SNVA and 4 
(80.4%) patients with persistent SNVA who developed lymphoproliferative features 
(p=0.0001).  
 
Eight patients (n=11; 72.7%) with persistent SNVA on histology received further treatment 
including steroids +/- immunosuppressants: Budesonide - 4 patients, budesonide and 6-
mercaptopurine: - 1, prednisolone and azathioprine - 2, prednisolone and adalimumab – 1. 
One patient received vedolizumab for a diagnosis of ulcerative colitis. Six patients (n=11; 
54.5%) underwent a repeat SBCE, which showed persistent changes on SBCE.  Another 
patient (n=11; 9.0%) had a normal repeat SBCE.  All 11 patients with persistent SNVA 
underwent repeat duodenal biopsies showing persistent VA. 
 
In the group of patients with persistent SNVA and lymphoproliferative features, 3 patients 
had a history of chronic lymphocytic leukaemia, large B-cell lymphoma and non-Hodgkin’s 
lymphoma respectively.  Two of them received budesonide and prednisolone, azathioprine 
respectively.  The same patients who received treatment also underwent a repeat SBCE that 
showed persistent changes of SNVA on SBCE. Another 2 patients developed 
angioimmunoblastic T-cell lymphoma and indolent mature B-Cell lymphoma after their 
diagnosis of SNVA.   
 
Group 2 (SNVA – CD): 
A total of 19.8% (35) of patients in this study had a histological response to a GFD and were 
therefore classified as having SNVA-CD.  Five of these patients (14%) were IgA deficient. 
The DY of SBCE in this group of patients was 51.4% (n=35; 18).  Seven  patients developed 
adverse events: 3 patients developed RCD I, and 2 developed RCD 2.  Two patients 
developed RCD 2 and ulcerative jejunoileitis. All had a positive SBCE at the time of 
diagnosis (p=0.022). They also had more extensive SB disease than those without adverse 
events (50% vs 1% p=0.002).  
 
Group 3 (identifiable cause): 
Thirty-seven patients (20.9%) had alternative causes for SNVA (Supplementary Table 1).  
The DY of SBCE in patients with identifiable causes for SNVA was 10 (27.0%). Three of 
these patients had SB ulcers secondary to H pylori, NSAIDs and Crohn’s disease 
respectively.  From those patients with a positive SBCE, who had repeat duodenal histology, 
only one patient had persistent SNVA.   
 
Group 4 (raised IELs+/- crypt hyperplasia): 
Fifty patients (28.2%) had raised IELs (Marsh class I).  In addition, 5 of these patients 
(10.0%) also had crypt hyperplasia (Marsh grade 2).  All patients had negative EMA and 
anti-TTG except for 4 patients who had a mean anti-TTG of 20 (U/mL). 
 
On repeat (36 patients) duodenal histology, 26 patients (72.2%) had normal histology after a 
mean of 45 +/-SD 40.8 months. Seven patients (19.4%) had persistence of Marsh 1 and 2 
disease, 1 patient (2.78%) had non-specific duodenitis on repeat histology.  Two patients 
(5.56%) had Marsh grade 3 disease.   
 
The DY of SBCE was only 14% (7 patients).  One patient had proximal VA.  Six patients had 
ulcers in their SB (4 distal, 1 mid, 1 diffuse). Two of these were eventually diagnosed with 
Crohn’s disease.  The others had underlying infective aetiologies including tuberculosis in 2 
patients.  
 
Three patients with a positive SBCE, had repeat duodenal histology that was normal.  Four 
patients with a normal SBCE had repeat duodenal histology which was normal in 3 cases.   
 
Causes for histological changes in group 4 can be found in Supplementary Table 2. 
 
Comparison of groups: 
There was no statistical difference in age at diagnosis across study groups (median age: group 
1: 50, group 2: 52, group 3: 51, group 4: 48.5 years; p=0.704).  The HLA status is shown in 
Supplementary Table 3 (p=0.0001).   There was no statistical difference in gender across 
groups (p=0.178).  Most patients were predominantly white (p=0.001, p=0.002) 
(Supplementary Tables 4 and 5). 
 
Patients with SNVA-UO and those with SNVA-CD were more likely to have positive 
SBCEs.  Those with raised IELs /crypt hyperplasia were more likely to have normal SBCEs 
(p=0.001) (table 2).  Patients with SNVA-UO and SNVA-CD also had the most-extensive 
disease (p=0.018) (table 2).  
 
Features of SNVA were similar in groups 1 (SNVA-UO) and 2 (SNVA-CD).  Patients in 
groups 3 (SNVA KNOWN CAUSE) and 4 (raised IELs +/- crypt hyperplasia) more 
commonly had ulcers (table 3).   
 
In patients with VA (groups 1–3), those with more severe histological pattern on duodenal 
biopsies were more likely to have a positive SBCE (PVA: 21, 26%, SVA: 12, 60%, TVA: 13, 
59%, p=0.001). More extensive SB disease also corresponded to a more severe histological 
pattern (PVA 1%, SVA 15%, TVA 17%, p=0.001). 
 
Eight (14.5%) patients within group 1 (SNVA-UO) had a positive second SBCE after a mean 
of 19 months (+/-SD 7.1).  These patients had their immunosuppressive medications altered.  
A third SBCE was carried out in 3 patients in group 1 (SNVA-UO after a mean of 14 months 
(+/-0.1)).  All of them had a positive SBCE.  All patients (5, 14.3%) who had a repeat SBCE 
within group 2 (SNVA-CD) had persistently positive findings (p=0.643).  This resulted in 
further dietary review to ensure strict adherence to a GFD.  Where this was confirmed and on 
reviewing histology, a diagnosis of RCD was made prompting commencement of steroids 
and immunosuppressants.   
 
Two patients in group 3 (SNVA-KNOWN CAUSE) (5.41%) had a repeat SBCE.  In one 
patient, the repeat SBCE was normal.  In another patient, florid ulceration was present.  This 
patient was diagnosed and started treatment for Crohn’s disease.  The first SBCE had also 
shown ulcers.  Three patients (6.0%) in group 4 (raised IELs +/- crypt hyperplasia) had repeat 
SBCEs. One patient had distal SB ulcers and was treated for TB.  This patient was not known 
to have TB before their investigations, and she was of Asian ethnicity.  Another patient had 
mosaic pattern of the mucosa proximally and had been on regular NSAIDs. Another patient 
had a normal SBCE. 
 
Overall, 11 patients (6.2%) passed away (all-cause mortality) by the end of the follow-up 
period. There was no statistical significant difference in mortality across groups (group 1: 3, 
5.5%, group 2: 4, 11.4%, group 3: 3, 8.1%, group 4: 1, 2.0% p=0.327).  However, when only 
deaths related to SNVA were considered, mortality was highest in the SNVA-CD group (3; 
8.6%) secondary to RCD adverse events.  One patient (1.8%) with SNVA-UO passed away 
from lymphoma (p=0.048).  None of the patients in groups 3 and 4 died from CD-related 
causes.  On constructing, survival curves for patients with SNVA-UO and SNVA-CD (CD-
related mortality), patients with extensive SB involvement had worse survival than those with 
normal or proximal involvement on SBCE (p=0.019) (figure 2).  There was no correlation 
between survival and severity of duodenal histology (p=0.793) (figure 3).   
 
Discussion: 
This study describes the findings on SBCE in subgroups of patients with different causes for 
SNVA in the SB, and in this aspect it is the first of its kind.  It highlights how SBCE at the 
time of diagnosis of SNVA can be important in the prediction of disease course and in the 
identification of features such as SB ulcers that need follow-up and could be consistent with 
other diagnoses such as Crohn’s disease. 
 
There are only 2 studies on the use of SBCE in patients with SNVA.  In a study by Kurien et 
al,(30) patients with equivocal CD were compared with patients with nonresponsive CD.  
Patients with equivocal CD were further subdivided into 32 patients with SNVA and 30 with 
Marsh grade 1 or 2 histology. In those patients with SNVA, 28% had a positive SBCE that 
showed features of CD or Crohn’s disease.  This is slightly lower than the overall DY 
reported in our study (group 1–3: 39.4%).  In patients with Marsh 1 and 2, 1 patient was 
diagnosed with CD and another with SB Crohn’s disease (30).  This is much lower than the 
DY we reported for a similar group of patients (14%).  In another study by Lujan-Sanchis et 
al,(31) 19 patients with SNVA-CD had a DY of 73.7%.  This is higher than the DY in our 
study for group 2 (SNVA-CD 51.4%).  One explanation for the difference in DY is the 
stricter diagnostic criteria that we used to diagnose SNVA-CD: histological response to a 
GFD.   
 
The utility of SBCE in subgroups of patients with SNVA was further assessed in our study.  
Patients with SNVA-UO and SNVA-CD where most likely to have positive SBCEs and they 
were likely to have the most extensive SB involvement unlike patients with an identifiable 
cause for SNVA and those with raised IELs +/-crypt hyperplasia.   Therefore, we can say that 
patients with SNVA who also have positive findings on SBCE are more likely to fall within 
one of these 2 groups of underlying etiology.  The cause of SNVA/Marsh 1 and 2 histology is 
not always established at the time of initial investigations.  Patients with a negative SBCE are 
more likely to have an underlying cause to explain the histological changes.  It is important 
that this is ruled out by means of a thorough history and secondary investigations such as 
further duodenal biopsies for TB.  In groups 3 and 4, SBCE was also helpful as it identified 
patients with SB ulcers.  Patients with a diagnosis of tuberculosis, were not known to have 
the condition before investigations for SNVA, Marsh 1 and 2 histology.  Those with changes 
secondary to NSAIDs use only admitted to their intake on further questioning.  It has been 
suggested that patients with SB ulcers will benefit from a repeat SBCE after at least 6 to 8 
months to ensure healing of the SB mucosa (32).   
 
In this study we have established a correlation between extent of SB disease and survival in 
patients with SNVA-UO and SNVA-CD.  However, we failed to establish a similar 
relationship with duodenal histology.  These findings establish an additional role for SBCE in 
predicting disease outcome. In patients with SNVA-UO, a positive SBCE was associated 
with persistent positive histology at follow-up.  This association highlights the fact that 
patients with macroscopic SB changes need to be targeted early with immunosuppressive 
therapy (7) due to the risk of persistent disease that in turn can be associated with risks of 
malabsorption and the development of lymphoproliferative disorders.  Patients with SNVA-
CD can develop adverse events such as RCD, ulcerative jejunoileitis, lymphoma and 
adenocarcinoma similar to patients with seropositive CD (33, 34).  All patients who 
eventually developed adverse events in the SNVA-CD group had a positive SBCE and they 
also had more extensive disease than patients with uncomplicated SNVA-CD.  These 
findings underline the important role SBCE can play in patients with SNVA-CD where the 
main treatment is a GFD.  Patients with SNVA-CD with a positive SBCE can be monitored 
more closely due to the higher risk of developing adverse events.   
 
Mortality in patients with SNVA has been compared to that in seropositive CD patients in 2 
studies (English and Italian studies), both confirming the higher mortality in the former 
group.  In one study the mortality in SNVA-CD, SNVA-non-CD, seropositive CD patients 
was 11.2%, 8.7% and 3.2% respectively (5).  In another study, mortality was 6 deaths /100 
person years in patients with SNVA, whereas only 0.2 deaths /100 person years were 
reported in seropositive CD patients (35).  These findings tie in with other differences that 
distinguish SNVA-CD and seropositive CD. The former patients tend to be older and have a 
higher risk of adverse events (36).  In our study, CD-related mortality was highest in the 
SNVA-CD group.  This is secondary to RCD-related adverse events. We were also able to 
inversely correlate survival in patients with SNVA-UO and SNVA-CD with extent of 
mucosal involvement on SBCE.  This confirms the importance of regularly screening patients 
with SNVA-CD for adverse events and managing those with extensive disease aggressively.   
 
A limitation of the study is the small cohort of patients included.  However, other studies on 
patients with SNVA undergoing SBCEs have included an even smaller number of patients 
(up to 32 with SNVA, 30 Marsh I, II) (30, 31).  Other limitations include the single center 
nature of this study and the broad time interval for data collection.  Expert capsule reviewers 
were also not blinded to the clinical findings, serology and duodenal histology results.  This 
might have resulted in over or under reporting of features of SNVA on SBCE.  Additionally, 
a few patients did not have HLA assays, and some of them did not have a second duodenal 
biopsy.  Not all patients with SNVA, raised IELs+/- crypt hyperplasia during the study period 
had a SBCE.  In addition, only a few patients had a repeat SBCE and repeat duodenal 
histology as decided by the caring physician which resulted in very small numbers of patients 
with repeat investigations.  A repeat SBCE is useful to reassess disease extent, assess 
response to therapy and in some cases (raised IELs+/- crypt hyperplasia) it can help to clarify 
the diagnosis. This made it difficult for us to draw any conclusions from features on repeat 
SBCEs.”   
 
Conclusion:  
SBCE can be useful in patients diagnosed with SNVA or Marsh 1 and 2 histology as it can 
identify features of CD or other conditions such as distal inflammation that can be associated 
with SB Crohn’s disease.  Unlike duodenal histology, SBCE can play an additional role in 
predicting disease outcome.  In patients with SNVA-UO, positive findings on SBCE and 
more extensive disease can predict those with persistent SNVA who will require treatment 
with immunosuppressants.  In SNVA-CD the same pattern is true for patients who eventually 
develop CD-related adverse events.  In both SNVA-CD and SNVA-UO, more extensive 
disease on SBCE is indicative of a poorer prognosis.  These patients need to be monitored 
more closely and alternative therapy such as steroids and immunosuppressants considered if 
adverse events develop.  Although the number of patients with repeat SBCE in this study is 
small, re-evaluation of disease extent using SBCE can result in modification of therapy in 




Features on SBCE N (%) 
Fissuring  13 (7.3) 
Scalloping  18 (10.2) 
Nodularity  3 (1.7) 
Mosaicism  20 (11.3) 
Villous atrophy 23 (13.0) 
Ulcers  16 (9.0) 
 
Region N (%) 
Proximal 33 (58.9) 
Proximal, mid 7 (12.5) 
Proximal, distal 1 (1.79) 
Mid  3 (5.36) 
Mid, distal 1 (1.79) 
Distal 6 (10.7) 
Diffuse 5 (8.93) 
Table 1: Features on capsule endoscopy in patients with raised IELs +/- crypt hyperplasia and 




 Findings of SNVA on SBCE (P = .001) Mean 
percentage 
extent of disease 
(P = .018)* 
Absent N (%) Present N (%) (%+/-SD) 
Group 1 (SNVA-UO) 33 (60.0) 22 (40.0) 10.2 (+/-26.5) 
Group 2 (SNVA-CD) 17 (48.6) 18 (51.4) 8.41 (+/-20.3) 
Group 3 (SNVA-KNOWN CAUSE) 27 (73.0) 10 (27.0) 5.49 (+/-22.9) 
Group 4 (Raised IELs +/- crypt 
hyperplasia) 
43 (86.0) 7   (14.0) 2.47 (+/-14.2) 

















Fissuring 8 (14.5) 5 (14.3) 0 (0) 0 (0) 0.0001 
Scalloping 11 (20.0) 6 (17.1) 1 (2.7) 0 (0) 0.0001 
Nodularity  1 (1.8) 2 (5.7) 0 (0) 0 (0) 0.185 
Mosaicism  10 (18.2) 10 (28.6) 0 (0) 0 (0) 0.0001 
Villous atrophy 11 (20.0) 7 (20.0) 4 (10.8) 1 (2.0) 0.012 
Ulcers  3 (5.7) 2 (5.7) 5 (13.9) 6 (12.0) 0.471 





Causes N (%) 
NSAIDs 5 (13.5) 
H pylori 13 (35.1) 
Giardia 6 (16.2) 
Tuberculosis 3 (8.1) 
Medications*  3 (8.1) 
Infective ** 4 (10.8) 
Crohn's disease 1 (2.7) 
Autoimmune 1 (2.7) 
Radiation enteritis 1 (2.7) 
Supplementary Table 1: Causes for SNVA in group 3; 
* Aspirin: 1 patient; Angiotensin receptor blocker: 2 patients;  
** Recent diagnosis of gastroenteritis: 2 patients; Positive duodenal aspirate (small intestinal 




Causes N (%) 
H pylori  6 (12) 
Celiac disease  2 (4) 
Tuberculosis  2 (4) 
Medications*  6 (12) 
Transient /Infective  10 (20) 
Crohn's disease  3 (6) 
Small intestinal bacterial overgrowth  2  (4) 
Sarcoidosis**   1 (2) 
Undiagnosed in   18 (36) 
Supplementary Table 2: Causes of raised intraepithelial lymphocytes +/- crypt hyperplasia in 
group 4; 



































4 (11.4) 0 (0) 10 (28.6) 2 (5.7) 15 (42.9) 1 (2.9) 3 (8.6)* 








0 (0) 1 (2.0) 18 (36.0) 5 (10.0) 5 (10.0) 0 (0) 21 (42.0) 
Supplementary Table 3: HLA status in patients with SNVA (p=0.0001); 
 
*Two of the patients who were HLA-DQ2, DQ8 negative in the SNVA-CD group were HLA 










Group 1 - SNVA-UO 50 (90.9) 5 (9.1) 
Group 2 - SNVA-CD 35 (100) 0 (0) 
Group 3 - SNVA-KNOWN 
CAUSE 
27 (73.0) 10 (27.0) 
Group 4 - Raised IELs +/-crypt 
hyperplasia 
39 (78.0) 11 (22.0) 
Supplementary Table 4: Ethnicity across different groups; p=0.001 
SNVA-UO: Seronegative villous atrophy of unknown cause; SNVA-CD: Seronegative 




























2 (3.6) 0 (0) 1 (1.8) 0 (0) 1 (1.8) 0 (0) 




0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0(0) 








8 (21.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 








3 (6.0) 2 (4.0) 0 (0) 1 
(2.0) 
4 (8.0) 1 (2.0) 
Supplementary Table 5: Ethnicity across different groups; p=0.002 
SNVA-UO: Seronegative villous atrophy of unknown cause; SNVA-CD: Seronegative 
villous atrophy secondary to celiac disease; IELs: intraepithelial lymphocytes.  
 
 
Figure 1: Algorithm for the diagnosis and management of patients with seronegative villous 
atrophy or having duodenal histology of Marsh 1 and 2; 
 
Figure 2: Mortality in group 1 (SNVA-UO) and 2 (SNVA-CD) from CD-related causes; 
(Normal: no features of SNVA on SBCE; proximal: features of SNVA in the proximal third 
of the small bowel; proximal and beyond or beyond proximal: features of SNVA that extend 
beyond the proximal small bowel or involve mid and distal small bowel;) 
 
Figure 3: Mortality in group 1 (SNVA-UO) and 2 (SNVA-CD) patients from CD-related 
causes according to severity of duodenal histology; (PVA: partial villous atrophy, SVA: 
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Seronegative villous atrophy (SNVA) 
Intraepithelial lymphocytes (IELs)  
Celiac disease (CD)  
Small bowel capsule endoscopy (SBCE) 
Small bowel (SB) 
Villous atrophy (VA) 
Refractory celiac disease (RCD) 
Duodenal bulb (D1) 
Second part of the duodenum (D2) 
Partial villous atrophy (PVA) 
Subtotal villous atrophy (SVA) 
Total villous atrophy (TVA) 
Endomysial antibodies (EMA) 
Iga tissue transglutaminase antibodies (TTG-igA) 
Gluten free diet (GFD) 
No identifiable cause for seronegative villous atrophy (SNVA-UO) 
 
